ecNumber*3.4.17.20#turnoverNumber*121#turnoverNumberMaximum*#substrate*bradykinin#commentary*#organism*Homo sapiens#ligandStructureId*466#literature*28942#!ecNumber*3.4.17.20#turnoverNumber*26#turnoverNumberMaximum*#substrate*hippuryl-L-Arg#commentary*#organism*Homo sapiens#ligandStructureId*2744#literature*28942#!ecNumber*3.4.17.20#turnoverNumber*52.4#turnoverNumberMaximum*#substrate*hippuryl-L-Arg#commentary*plasma-derived enzyme#organism*Homo sapiens#ligandStructureId*2744#literature*28933#!ecNumber*3.4.17.20#turnoverNumber*56.7#turnoverNumberMaximum*#substrate*hippuryl-L-Arg#commentary*recombinant enzyme#organism*Homo sapiens#ligandStructureId*2744#literature*28933#!ecNumber*3.4.17.20#turnoverNumber*2.67#turnoverNumberMaximum*#substrate*hippuryl-Arg#commentary*#organism*Homo sapiens#ligandStructureId*3376#literature*700206#!ecNumber*3.4.17.20#turnoverNumber*2.74#turnoverNumberMaximum*#substrate*hippuryl-Arg#commentary*#organism*Bos taurus#ligandStructureId*3376#literature*700206#!ecNumber*3.4.17.20#turnoverNumber*0.00004#turnoverNumberMaximum*#substrate*hippuryl-arginine#commentary*mutant S90D/S94V/S90D, activation of TAFI by plasmin#organism*Homo sapiens#ligandStructureId*5050#literature*699871#!ecNumber*3.4.17.20#turnoverNumber*0.00008#turnoverNumberMaximum*#substrate*hippuryl-arginine#commentary*mutant S90P, activation of TAFI by plasmin#organism*Homo sapiens#ligandStructureId*5050#literature*699871#!ecNumber*3.4.17.20#turnoverNumber*0.0002#turnoverNumberMaximum*#substrate*hippuryl-arginine#commentary*mutant P91S, activation of TAFI by plasmin#organism*Homo sapiens#ligandStructureId*5050#literature*699871#!ecNumber*3.4.17.20#turnoverNumber*0.0003#turnoverNumberMaximum*#substrate*hippuryl-arginine#commentary*mutant S94V, activation of TAFI by plasmin#organism*Homo sapiens#ligandStructureId*5050#literature*699871#!ecNumber*3.4.17.20#turnoverNumber*0.00039#turnoverNumberMaximum*#substrate*hippuryl-arginine#commentary*mutant R92K, activation of TAFI by plasmin#organism*Homo sapiens#ligandStructureId*5050#literature*699871#!ecNumber*3.4.17.20#turnoverNumber*0.00042#turnoverNumberMaximum*#substrate*hippuryl-arginine#commentary*wild-type, activation of TAFI by plasmin#organism*Homo sapiens#ligandStructureId*5050#literature*699871#!ecNumber*3.4.17.20#turnoverNumber*0.00043#turnoverNumberMaximum*#substrate*hippuryl-arginine#commentary*mutant A93V, activation of TAFI by plasmin#organism*Homo sapiens#ligandStructureId*5050#literature*699871#!ecNumber*3.4.17.20#turnoverNumber*15#turnoverNumberMaximum*#substrate*Hippuryl-L-Lys#commentary*#organism*Homo sapiens#ligandStructureId*6536#literature*28942#!ecNumber*3.4.17.20#turnoverNumber*40.7#turnoverNumberMaximum*#substrate*Hippuryl-L-Lys#commentary*plasma-derived enzyme#organism*Homo sapiens#ligandStructureId*6536#literature*28933#!ecNumber*3.4.17.20#turnoverNumber*45.6#turnoverNumberMaximum*#substrate*Hippuryl-L-Lys#commentary*recombinant enzyme#organism*Homo sapiens#ligandStructureId*6536#literature*28933#!ecNumber*3.4.17.20#turnoverNumber*0.205#turnoverNumberMaximum*#substrate*p-anisylazoformyl-L-arginine#commentary*mutant A93V, activation of TAFI by thrombin in the presence of thrombomodulin#organism*Homo sapiens#ligandStructureId*7011#literature*699871#!ecNumber*3.4.17.20#turnoverNumber*0.215#turnoverNumberMaximum*#substrate*p-anisylazoformyl-L-arginine#commentary*mutant R92K, activation of TAFI by thrombin in the presence of thrombomodulin#organism*Homo sapiens#ligandStructureId*7011#literature*699871#!ecNumber*3.4.17.20#turnoverNumber*0.315#turnoverNumberMaximum*#substrate*p-anisylazoformyl-L-arginine#commentary*wild-type, activation of TAFI by thrombin in the presence of thrombomodulin#organism*Homo sapiens#ligandStructureId*7011#literature*699871#!ecNumber*3.4.17.20#turnoverNumber*0.328#turnoverNumberMaximum*#substrate*p-anisylazoformyl-L-arginine#commentary*mutant S94V, activation of TAFI by thrombin in the presence of thrombomodulin#organism*Homo sapiens#ligandStructureId*7011#literature*699871#!ecNumber*3.4.17.20#turnoverNumber*0.377#turnoverNumberMaximum*#substrate*p-anisylazoformyl-L-arginine#commentary*mutant S90P, activation of TAFI by thrombin in the presence of thrombomodulin#organism*Homo sapiens#ligandStructureId*7011#literature*699871#!ecNumber*3.4.17.20#turnoverNumber*15.9#turnoverNumberMaximum*#substrate*anisylazoformyl-Lys#commentary*24&Acirc;&deg;C#organism*Homo sapiens#ligandStructureId*7570#literature*652361#!ecNumber*3.4.17.20#turnoverNumber*26.8#turnoverNumberMaximum*#substrate*anisylazoformyl-Lys#commentary*24&Acirc;&deg;C#organism*Homo sapiens#ligandStructureId*7570#literature*652361#!ecNumber*3.4.17.20#turnoverNumber*27#turnoverNumberMaximum*#substrate*anisylazoformyl-Lys#commentary*24&Acirc;&deg;C#organism*Homo sapiens#ligandStructureId*7570#literature*652361#!ecNumber*3.4.17.20#turnoverNumber*27.4#turnoverNumberMaximum*#substrate*anisylazoformyl-Lys#commentary*24&Acirc;&deg;C#organism*Homo sapiens#ligandStructureId*7570#literature*652361#!ecNumber*3.4.17.20#turnoverNumber*29.5#turnoverNumberMaximum*#substrate*anisylazoformyl-Lys#commentary*24&Acirc;&deg;C#organism*Homo sapiens#ligandStructureId*7570#literature*652361#!ecNumber*3.4.17.20#turnoverNumber*29#turnoverNumberMaximum*#substrate*N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys#commentary*#organism*Homo sapiens#ligandStructureId*9224#literature*28942#!ecNumber*3.4.17.20#turnoverNumber*248#turnoverNumberMaximum*#substrate*N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys#commentary*recombinant enzyme#organism*Homo sapiens#ligandStructureId*9224#literature*28933#!ecNumber*3.4.17.20#turnoverNumber*293#turnoverNumberMaximum*#substrate*N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys#commentary*plasma-derived enzyme#organism*Homo sapiens#ligandStructureId*9224#literature*28933#!ecNumber*3.4.17.20#turnoverNumber*169#turnoverNumberMaximum*#substrate*Hippuryl-L-argininic acid#commentary*#organism*Homo sapiens#ligandStructureId*15782#literature*28942#!ecNumber*3.4.17.20#turnoverNumber*748#turnoverNumberMaximum*#substrate*Arg6-Leu5-enkephalin#commentary*#organism*Homo sapiens#ligandStructureId*29755#literature*28942#!ecNumber*3.4.17.20#turnoverNumber*647#turnoverNumberMaximum*#substrate*Arg6-Met5-enkephalin#commentary*#organism*Homo sapiens#ligandStructureId*29756#literature*28942#!ecNumber*3.4.17.20#turnoverNumber*282#turnoverNumberMaximum*#substrate*Lys6-Leu5-enkephalin#commentary*#organism*Homo sapiens#ligandStructureId*30161#literature*28942#!ecNumber*3.4.17.20#turnoverNumber*290#turnoverNumberMaximum*#substrate*Lys6-Met5-enkephalin#commentary*#organism*Homo sapiens#ligandStructureId*30162#literature*28942#!ecNumber*3.4.17.20#turnoverNumber*36#turnoverNumberMaximum*#substrate*N-[3-(2-Furylacryloyl)]-L-Ala-L-Arg#commentary*#organism*Homo sapiens#ligandStructureId*30207#literature*28942#!ecNumber*3.4.17.20#turnoverNumber*64#turnoverNumberMaximum*#substrate*N-benzoyl-Gly-L-Arg#commentary*in 50 mM HEPES (pH 8.0) at 25&Acirc;&deg;C#organism*Homo sapiens#ligandStructureId*31564#literature*707113#!ecNumber*3.4.17.20#turnoverNumber*2.3#turnoverNumberMaximum*#substrate*biotinyl-(epsilon-aminocaproic acid)-(epsilon-aminocaproic acid)-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Arg-OH#commentary*room temperature#organism*Homo sapiens#ligandStructureId*33949#literature*649320#!ecNumber*3.4.17.20#turnoverNumber*59#turnoverNumberMaximum*#substrate*N-benzoyl-2'-cyano-L-Phe-L-Arg#commentary*in 50 mM HEPES (pH 8.0) at 25&Acirc;&deg;C#organism*Homo sapiens#ligandStructureId*40532#literature*707113#